Therapy-induced alterations in host defense in children receiving therapy for cancer

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 5, 1997, Pages 399-417

  Lehrnbecher, Thomas ^a,b   Foster, Charles ^b   Vázquez, Nancy ^b   Mackall, Crystal L ^b   Chanock, Stephen J ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CARMUSTINE; CD4 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 8; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

B LYMPHOCYTE; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; COMPLEMENT SYSTEM; HEMATOPOIESIS; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL; PHAGOCYTE; PRIORITY JOURNAL; REVIEW;

B-LYMPHOCYTES; CHILD; COMMUNICABLE DISEASES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; KILLER CELLS, NATURAL; NEOPLASMS; PHAGOCYTES; RISK FACTORS; THERAPEUTICS;

EID: 0031431191     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199709000-00001     Document Type: Review

References (288)

1. Freifeld A, Hathorn J, Pizzo P. Infectious complications in the pediatric cancer patient. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology. Philadelphia: J.B. Lippincott Co., 1993:987-1020.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
3. Young L. Management of infections in leukemia and lymphoma. In: Rubin R, Young L, eds. Clinical Approach to Infection in the Compromised Host 2nd ed. New York: Plenum Publisher, 1994:551-80.
4. Hersh E, Whitecar J, McCredie K, et al. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 1971;285:1211-6.
5. Magrath IT, Simon R. Immunosuppression in Burkitt's lymphoma. II. Peripheral blood lymphocyte populations related to clinical status. Int J Cancer 1976;18:399-408.
6. Fuks Z, Strober S, Bobrove AM, et al. Long term effects of radiation on T and B lymphocytes in the peripheral blood of patients with Hodgkin's disease. J Clin Invest 1976;58:803-7.
7. Kung F, Orgel H, Wallace W, et al. Antibody production following immunization with diphtheria and tetanus toxoids in children receiving chemotherapy during remission of malignant disease. Pediatrics 1984;74:86-9.
8. Pizzo PA, Rubin M, Freifeld A, et al. The child with cancer and infection. II. Nonbacterial infections. J Pediatr 1991;119:845-57.
9. Pizzo PA, Rubin M, Freifeld A, et al. The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:679-94.
10. Siber G, Weitzman S, Aisenberg A, et al. Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease. N Engl J Med 1978;299:442-8.
11. Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer. Oncology 1996;10:599-606.
12. Donaldson S, Glatstein E, Vosti K. Bacterial infections in pediatric Hodgkin's disease: relationship to radiotherapy, chemotherapy and splenectomy. Cancer 1978;41:1949-58.
13. Chanock S, Pizzo P. Infection prevention strategies for children with cancer and AIDS: contrasting dilemmas. J Hosp Infect 1995; 30: S197-208.
14. Feldman S, Gigliotti F, Shenep J, et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990;161:926-31.
15. Gross P, Gould A, Brown A. Effect of cancer chemotherapy on the immune response to influenza vaccine: review of published studies. Rev Inf Dis 1985;7:613-8.
16. Orgel H, Hamburger RN, Mendelson LM, et al. Antibody response in normal infants and in infants receiving chemotherapy for congenital neuroblastoma. Cancer 1977;40:994-7.
17. Ogra P, Sinks L, Karzon D. Poliovirus antibody response in patients with acute leukemia. J Pediatr 1971;79:444-9.
18. Siber G. Bacteremias due to Haemophilus influenzae and Streptococcus pneumoniae. Their occurrence and course in children with cancer. Am J Dis Child 1980;134:668-72.
19. Van der Does-van den Berg A, Hermans J, Nagel J, et al. Immunity to diphtheria, pertussis, tetanus, and poliomyelitis in children with acute lymphocytic leukemia after cessation of chemotherapy. Pediatrics 1981;67:222-9.
20. Chanock S, Gorlin J. Granulocyte transfusions: Time for a second look. Infect Dis Clin North Am 1996;10:327-43.
21. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
22. Schimpff S, Satterlee W, Young V, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
23. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-14.
24. Pizzo PA, Robichaud KJ, Wesley R, et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore) 1982;61:153-65.
25. Van der Meer J, Allenman M, Boekhout M. Infectious episodes in severely granulocytopenic patients. Infection 1979;7:171-5.
26. Pizzo PA. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient. J Pediatr 1981;98:341-54.
27. Buchanan GR. Approach to the treatment of the febrile cancer patient with low-risk neutropenia. In: Pizzo PA, ed. Infectious Complications in the Immunocompromised Host. Philadelphia: W.B. Saunders Company, 1993:919-36.
28. Klastersky J. Concept of empiric therapy with antibiotic combinations: Indications and limits. Am J Med 1986;80 (S5):2-11.
29. Chanock S, Pizzo P. Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Semin Oncol 1997;24:132-40.
30. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment for Cancer. Eur J Cancer 1994;30:430-7.
31. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996;14:919-24.
32. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. N Engl J Med 1993;329: 1437-41.
33. Bash RO, Katz JA, Cash JV, et al. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-96.
34. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
35. Talcott J, Finberg R, Mayer R, et al. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8.
36. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
37. Chanock S. Evolving risk factors for infectious complications of cancer therapy. In: Pizzo PA, ed. Infectious Complications in the Immunocompromised Host. Philadelphia: W.B. Saunders Company, 1993:771-94.
38. Chanock SJ, Pizzo P. Fever in the neutropenic host. Infect Dis Clin North Am 1996;10:777-96.
39. Gebbia V, Testa A, Valenza R, et al. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 1993;5:186-90.
40. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
41. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
42. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [abstract]. Blood 1993;82:2329-39.
43. Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929-40.
44. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
45. Miller L. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1994;7:67-83.
46. Chanock S, Freifeld A. The use of cytokines in fever and neutropenia. International Journal of Pediatric Hematology/Oncology 1995;2: 173-83.
47. Ichinose Y, Hara N, Motohiro A, et al. Influence of chemotherapy on superoxide anion-generating activity of polymorphonuclear leukocytes in patients with lung cancer. Cancer 1986;58:1663-7.
48. Pickering L, Anderson D, Choi S, et al. Leukocyte function in children with malignancies. Cancer 1975;35:1365-71.
49. Heilmann C, Pedersen F. Granulocyte function in children with acute lymphoblastic leukemia during remission. Scandinavian Journal of Hematology 1980;25:30-4.
50. Powell B, Olbrantz P, Bicket D, et al. Altered oxidative product formation in neutrophils of patients recovering from therapy for acute leukemia. Blood 1986;67:1624-30.
51. Thompson E, Williams R. Bactericidal capacity of peripheral blood leukocytes in relation to bactericidal infections in acute lymphoblastic leukemia in childhood. J Clin Pathol 1974;27:906-10.
52. Baehner R, Newburger P, Johnson D, et al. Transient bactericidal defect of peripheral blood phagocytes from children with acute lymphoblastic leukemia receiving craniospinal irradiation. N Engl J Med 1973;289:1209-13.
53. Vaudaux P, Kiefer B, Forni M, et al. Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils. Cancer 1984;54:400-10.
54. Whittaker J, Hughes H, Khurshid M. The effect of cytotoxic antiinflammatory drugs on the phagocytosis of neutrophil leukocytes. Br J Haematol 1975;29:273-8.
55. MacFadden D, Saito S, Pruzanski W. The effect of chemotherapeutic agents on chemotaxis and random migration of human leukocytes. J Clin Oncol 1985;3:415-9.
56. Pruzanski W, Saito S, Deboer G. Modulatory activity of chemotherapeutic agents on phagocytosis and intracellular bactericidal activity of human polymorphonuclear and mononuclear phagocytes. Cancer Res 1983;43:1420-5.
57. Pickering L, Ericsson C, Kohl S. Effect of chemotherapeutic agents on metabolic and bactericidal activity of polymorphonuclear leukocytes. Cancer 1978;42:1741-6.
58. Hara N, Ichinose Y, Motohiro A, et al. Influence of chemotherapeutic agents on superoxide anion production by human polymorphonuclear leukocytes. Cancer 1990;66:684-8.
59. Hyams J, Donaldson M, Metcalf J, et al. Inhibition of human granulocyte function by methotrexate. Cancer Res 1978;38:650-5.
60. Johnson J, Summersgill J, Raff M. The in vitro effects of methotrexate on the phagocytosis and intracellular killing of Staphylococcus aureus by human neutrophils. Cancer 1986;57:2342-5.
61. Hersh E, Wong V, Freireich E. Inhibition of local inflammatory response in man by antimetabolites. Blood 1966;27:38-48.
62. Losito A, Williams D, Cooke G, et al. The effects on polymorphonuclear leukocyte function of prednisolone, azathioprine and 6-mercaptopurine in vivo. Clin Exp Immunol 1978;32:423-8.
63. Johnson W, DiMartino M, Meunier P, et al. Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 1988;15:745-9.
64. Nesher G, Moore TL, Dorner RW. In vitro effects of methotrexate on peripheral blood monocytes. Ann Rheum Dis 1991;50:637-41.
65. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993;92:223-8.
66. Abzug MJ, Cotton MF. Severe chickenpox after intranasal use of corticosteroids. J Pediatr 1993;123:577-9.
67. Gershon A, Brunell P, Doyle E. Steroid therapy and varicella. J Pediatr 1972;81:1034.
68. Finkel K. Mortality from varicella in children receiving adrenocorticosteroids and adrenocorticotropin. Pediatrics 1961;28:436-44.
69. Fleisher G, Henry W, McSorley M, et al. Life-threatening complications of varicella. Am J Dis Child 1981;135:896-9.
70. Herrold JM, Hahn JS. Disseminated multifocal herpes zoster leukoencephalitis and subcortical hemorrhage in an immunosuppressed child. J Child Neurol 1994;9:56-8.
71. Walsh TJ. Management of immunocompromised patients with evidence of invasive mycosis. In: Pizzo PA, ed. Infectious Complications in the Immunocompromised Host. Philadelphia: W.B. Saunders Company, 1993:1003-26.
72. Berenguer J, Allende M, Lee J, et al. Pathogenesis of pulmonary aspergillosis: granulocytopenia versus cyclosporine and methylprednisolonone-induced immunosuppression. Am J Respir Crit Care Med 1995;152:1079-86.
73. Nesbitt LT, Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995;13:925-39.
74. Bishop CR, Athens JW, Boggs DR, et al. Leukokinetic studies. 13. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest 1968;47:249-60.
75. Dale D, Fauci A, Wolff S. Alternative-day prednisone:leukocyte kinetics and susceptibility to infections. N Engl J Med 1974;291: 1154-8.
76. Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995;86:3181-8.
77. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995;154:4719-25.
78. Wiener S, Wiener R, Urivetzky M, et al. The mechanism of action of a single dose of methylprednisolone on acute inflammation in vivo. J Clin Invest 1975;56:679-89.
79. Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood 1978;51:771-9.
80. Nelson DH, Meikle AW, Benowitz B, et al. Cortisol and dexamethasone suppression of superoxide anion production by leukocytes from normal subjects. Trans Assoc Am Physicians 1978;91:381-7.
81. Miller DR, Kaplan HG. Decreased nitroblue tetrazolium dye reduction in the phagocytes of patients receiving prednisone. Pediatrics 1970;45:861-5.
82. MacGregor R, Spagnuolo P, Lentek A. Inhibition of granulocyte adherence by ethanol, prednisone, and aspirin, measured with an assay system. N Engl J Med 1974;291:642-6.
83. Oseas RS, Allen J, Yang HH, et al. Mechanism of dexamethasone inhibition of chemotactic factor induced granulocyte aggregation. Blood 1982;59:265-9.
84. Rinehart J, LoBuglio A. Effects of corticosteroids on human monocyte chemotaxis. Clin Research 1973;21:878.
85. Bass D. Eosinophil behavior during host defense reactions. In: Gallin J, Fauci A, eds. Advances in Host Defense Mechanisms. New York: Raven Press, 1982:211-41.
86. Rinehart J, Sagone A, Balcerzak S, et al. Effects of corticosteroid therapy on human monocyte function. N Engl J Med 1975;292:236-41.
87. Thompson J, van Furth R. The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med 1970;131:429-42.
88. Ponzin D, Bellini F, Chizzolini C. Antigen presentation is inhibited in vivo by betamethasone. Life Sci 1995;56:1595-9.
89. Knudsen P, Dinarello C, Strom T. Glucocorticoids inhibit transcriptional and posttranscriptional expression of interleukin-1 in U-937 cells. J Immunol 1987;139:4129-35.
90. Bemelmans MH, Abramowicz D, Gouma DJ, et al. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies. J Immunol 1994;153:499-506.
91. Bishop GA, Hall BM. Effect of immunosuppressives on gamma-interferon production, lymphocyte proliferation, and cytotoxic function of activated T lymphocytes. Transplant Proc 1987;19:2866-8.
92. Cesario TC, Slater L, Poo WJ, et al. The effect of hydrocortisone on the production of gamma-interferon and other lymphokines by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1986; 6:337-47.
93. Wakiguchi H, Kubota H, Hisakawa H, et al. Defective natural killer cell activity and deficient production of interferon-gamma in children with acute lymphoblastic leukemia. Acta Paediatr Jpn 1994;36:361-5.
94. Penny R, Gallon DA. Studies on neutrophil function. II. Pathological aspects. Br J Haematol 1966;12:633-45.
95. Coiffier B, Frobert Y, Revol L. Polymorphonuclear function in acute myeloblastic leukemia. Biomedicine 1977;27:94-6.
96. Holland JF, Senn H, Banerjee T. Quantitative studies of localized leukocyte mobilization in acute leukemia. Blood 1971;37:499-511.
97. Solberg CO, Schreiner K, Hellum KB, et al. Neutrophil granulocyte function in the early diagnosis of acute myelomonocytic and myeloblastic leukaemia. Acta Med Scand 1975;197:147-51.
98. Rosner F, Valmont I, Kozinn PJ, et al. Leukocyte function in patients with leukemia. Cancer 1970;25:835-42.
99. Tornyos K. Phagocytic activity of cells of the inflammatory exudate in human leukemia. Cancer Res 1967;27:1756-60.
100. Wilkinson PM, Sumner C, Delamore IW, et al. Granulocyte function in myeloblastic leukaemia. Br J Cancer 1975;32:574-7.
101. Goldman J, Th'Ng K. Phagocytic function of leucocytes from patients with acute myeloid and chronic granulocytic leukemia. Br J Haematol 1973;25:299-308.
102. Braude AI, Feltes J, Brooks M. Differences between the activities of mature granulocytes in leukemic and normal blood. J Clin Invest 1954;33:1036-46.
103. McCormack R, Nelson R, Bloomfield C, et al. Neutrophil function in lymphoreticular malignancy. Cancer 1979;44:920-6.
104. Reid M, Craft A, Low W. Neutrophil function in children with acute lymphoblastic leukemia in presence and absence of viral infections. Arch Dis Child 1979;54:619-22.
105. Seidner D, Mascioli E, Istfan N, et al. Effects of long-term triglyceride emulsions on reticuloendothelial system function in humans. J Parenteral Enteral Nutrition 1989;13:614-9.
106. Stephan RN, Kisala JM, Dean RE, et al. Effect of blood transfusion on antigen presentation function and on interleukin 2 generation. Arch Surg 1988;123:235-40.
107. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990;30:651-8.
108. Esber E, DiNicola W, Movassaghi N, et al. T and B lymphocytes in leukemia therapy. Am J Hematol 1976;1:211-8.
109. Chung HS, Higgins GR, Siegel SE, et al. Abnormalities of the immune system in children with neuroblastoma related to the neoplasm and chemotherapy. J Pediatr 1977;90:548-54.
110. Simone JV, Aur RJA, Husto HO, et al. Combined modality therapy of acute lymphoblastic leukemia. Cancer 1975;35:25-35.
111. Craft AW, Reid MM, Bruce E, et al. Role of infection in the death of children with acute lymphoblastic leukaemia. Arch Dis Child 1977;52:752-7.
112. Ninane J, Chessels JM. Serious infections during continuing treatment of acute lymphoblastic leukaemia. Arch Dis Child 1981; 56:841-4.
113. Strender LE, Blomgren H, Petrini B, et al. Immunologic monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer 1981;48:1996-2002.
114. Petrini B, Wasserman J, Blomgren H, et al. T helper/suppressor ratios in chemotherapy and radiotherapy. Clin Exp Immunol 1983; 53:255-6.
115. Steis RG, Urba WJ, Kopp WC, et al. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 1991;83:1678-9.
116. Diamond RD. Immune response to fungal infection. Rev Infect Dis 1989;11:S1600-4.
117. Blay JY, Chauvin F, Cesne AL, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996;14:636-43.
118. Ivy SP, Mackall CL, Gore L, et al. Demodicidosis in childhood acute lymphoblastic leukemia: an opportunistic infection occurring with immunosuppression. Pediatrics 1995;127:751-4.
119. Bhavnani M, Morris-Jones PH, Testa NG. Children in long-term remission after treatment for acute lymphoblastic leukaemia show persisting haemopoietic injury in clonal and long-term cultures. Br J Haematol 1989;71:37-41.
120. Katz J, Walter BO, Bennetts GA, et al. Abnormal cellular and humoral immunity in childhood acute lymphoblastic leukemia in long-term remission. West J Med 1987;146:179-87.
121. Hughes W, Feldman S, Aur R, et al. Intensity of immunosuppressive therapy and incidence of Pneumocvstis carinii pneumonia. Cancer 1975;36:2004-9.
122. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid Therapy: Mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-15.
123. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832-7.
124. Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis pneumonia in patients with primary brain tumors. Arch Neurol 1991;48:406-9.
125. Mackall C, Fleisher T, Brown M, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-8.
126. Allende M, Pizzo PA, Horowitz M, et al. Pulmonary cryptococcosis presenting as metastases in children with sarcomas. Pediatr Infect Dis J 1993;12:240-3.
127. Browne M, Hubbard S, Longo D, et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann Intern Med 1986;104:338-44.
128. Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant human GM-CSF and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992;10:464-73.
129. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971;285:1493-6.
130. Gershwin M, Goetzl E, Steinberg A. Cyclophosphamide: use in practice. Ann Intern Med 1974;80:531-40.
131. Layward L, Levinsky R, Butler M. Long-term abnormalities in T and B lymphocyte function in children following treatment for acute lymphoblastic leukemia. Br J Haematol 1981;49:251-8.
132. Boldt DH, Von Hoff DD, Kuhn JG, et al. Effects on human peripheral lymphocytes of in vivo administration of 9-b-D-Arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984;44:4661-6.
133. Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989;73:38-46.
134. Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990;8:848-55.
135. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-48.
136. Slater J, Ngo E, Lau B. Effect of therapeutic irradiation on the immune responses. Am J Roentgenol 1976;126:313-20.
137. Reckzeh B, Merte H, Pfluger KH, et al. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996;14:1071-6.
138. Cranedonk E, van Gennip AH, Abeling NGGM, et al. Numerical changes in the various peripheral white blood cells in children as a result of antineoplastic therapy. Acta Haematol 1984;72:315-25.
139. Alanko S, Pelliniemi T-T, Salmi T. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 1992;69:1481-6.
140. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
141. Grubman S, Oleske JM, Simonds RJ, et al. Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995;44:1-11.
142. Erkeller-Yuksel FM, Deneys V, Hannet I, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992;120:216-22.
143. Thomas P, Singh T, Williams R, et al. Trends in survival for children reported with maternally transmitted acquired immunodeficiency syndrome in New York City, 1982 to 1989. Pediatr Infect Dis J 1992;11:34-9.
144. McKinney RE, Wilfert CM. Lymphocyte subsets in children younger than 2 years old: normal values in a population at risk for human immunodeficiency virus infection and diagnostic and prognostic application to infected children. Pediatr Infect Dis J 1992;11:639-44.
145. Leggiadro RJ, Winkelstein JA, Hughes WT. Prevalence of Pneumocystis carinii pneumonitis in severe combined immunodeficiency. J Pediatr 1981;99:96-8.
146. Fishman J. Pneumocystis carinii and parasitic infections in the immunocompromised host. In: Rubin R, Young L, eds. Clinical Approach to Infection in the Immunocompromised Host. New York: Plenum Publishers, 1994:275-334.
147. Brunvand MW, Collins C, Livingston RB, et al. Pneumocystis carinii pneumonia associated with profound lymphopenia and abnormal T-lymphocyte subset ratios during treatment for early-stage breast carcinoma. Cancer 1991;67:2407-9.
148. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N Engl J Med 1990;323:833-4.
149. Borzy M, Ridgway D. Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia. Blood 1989;73:1608-14.
150. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997 (in press).
151. Leino L, Lilius EM, Nikoskelainen J, et al. The reappearance of 10 differentiation antigens on peripheral blood lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant 1991;8:339-44.
152. Bengtsson M, Totterman TH, Smedmyr B, et al. Regeneration of functional and activated NK and T-sub-subset cells in the marrow and blood after autologous bone marrow transplantation: A prospective phenotypic study with 2/3-color FACS analysis. Leukemia 1989;3:68-75.
153. Mackall CL, Granger L, Sheard MA, et al. T cell regeneration after bone marrow transplantation: Differential CD45 isoform expression on thymic-derived versus thymic-independent progeny. Blood 1993;82:2585-94.
154. Mackall C, Fleisher T, Brown M, et al. Age, thymopoiesis, and CD 4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
155. Borella L, Green A, Webster R. Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. Blood 1972;40:42-51.
156. Storek J, Whitherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995;16:413-25.
157. Weinberg K, Annett G, Kashyap A, et al. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marr Transplant 1995;1:18-23.
158. Mackall CL, Bare CV, Titus JA, et al. Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;156:4609-16.
159. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post chemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997 (in press).
160. Sagerstrom CG, Kerr EM, Allison JP, et al. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A 1993;90:8987-91.
161. Smith S, Schiffman G, Karayalcin G, et al. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster therapy. J Pediatr 1995;127:68-75.
162. Bowden R, Levin M, Giller R, et al. Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukemic patients. Clin Exp Immunol 1985;60:387-95.
163. Masur H. Prevention of Pneumocystis carinii pneumonia. Rev Inf Dis 1989;11:S1664-8.
164. Ritz J. The role of natural killer cells in immune surveillance. N Engl J Med 1989;320:1748-9.
165. Biron C, Byron K, Sullivan J. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-5.
166. Jacobs R, Stoll M, Stratmann G, et al. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.
167. Niederwieser D, Gastl G, Rumpold H, et al. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 1987;65:301-5.
168. Dickinson A, Proctor S, Jacobs E, et al. Natural killer cell activity in childhood acute lymphoblastic leukemia in remission. Br J Haematol 1985;59:45-53.
169. Komada Y, Zhang S-L, Zhou Y-W, et al. Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy. Cancer Immunol Immunother 1992; 35:271-6.
170. Alanko S, Salmi T, Pelliniemi T-T. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumor. Med Pediatr Oncol 1995;24:373-8.
171. Sorskaar D, Forre O, Lie S. Increased natural killer cell activity and numbers of Leu-7 and Leu-11b (CD16)-positive cells in bone marrow of children in remission from acute lymphoblastic leukemia. Scand J Immunol 1989;29:65-72.
172. Cseuz R, Panayi G. The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis. Br J Rheumatol 1990;30:58-62.
173. Garzetti GG, Ciavattini A, Provinciali M, et al. Influence of neoadjuvant polychemotherapy on natural killer cell activity in patients with locally advanced cervical squamous carcinoma. Gynecol Oncol 1994;52:39-43.
174. Yabuhara A, Kawai H. A recycling defect as a characteristic of natural killer cells in childhood acute lymphoblastic leukemia. Pediatr Res 1990;28:572-8.
175. Yamada S, Kawai H, Miyagawa Y, et al. Effect of radiotherapy on natural killer activity in childhood acute lymphoblastic leukemia and lymphoma. Leuk Lymphoma 1991;4:343-9.
176. Schur PH, Borel H, Gelfand EW, et al. Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med 1970;283:631-4.
177. Abrahamsson J, Marky I, Mellander L. Immunoglobulin levels and lymphocyte response to mitogenic stimulation in children with malignant disease during treatment and follow-up. Acta Paediatr 1995;84:177-82.
178. Hitzig W, Pluss H, Joller P, et al. Studies on the immune status of children with acute lymphocytic leukemia. Clin Exp Immunol 1976;26:414-8.
179. Reid M, Craft A, Todd J. Serial studies of number of circulating T and B lymphocytes in children with acute lymphoblastic leukemia. Arch Dis Child 1977;52:245-7.
180. Rosen F, Cooper M, Wedgwood R. The primary immunodeficiencies (part 2). N Engl J Med 1984;311:300-10.
181. Saarinen UM. Severe infections in childhood leukemia. A follow-up study of 100 consecutive ALL patients. Acta Paediatr Scand 1984;73:515-22.
182. Weitzman S, Aisenberg A. Fulminant sepsis after the successful treatment of Hodgkin's disease. Am J Med 1977;62:47-50.
183. Weisman S, Gates L, Allegretta G, et al. Antibody response to immunization with Haemophilus influenzae type b polysaccharide vaccine in children with cancer. J Pediatr 1987;111:727-9.
184. King BR, Bell LM, Marshall GS. Haemophilus influenzae type b bacteremia in older children. Pediatr Emerg Care 1991;7:331-3.
185. Chilcote R, Baehner R, Hammond D. Septicemia and meningitis in children splenectomized for Hodgkin's disease. N Engl J Med 1976;295:798-800.
186. Van der Meer JWM. Infections in splenectomised patients: guidelines for management. Clin Invest Med 1993;71:1-2.
187. Demeter J, Paloczi K, Lehoczky D, et al. Observations on NK cells, K cells and on their function a long time after posttraumatic splenectomy. Int Arch Allergy Immunol 1990;92:287-92.
188. Domelloef L, Athlin L. The effect of combination chemotherapy on the reticuloendothelial system in man. Cancer Lett 1978;5:7-11.
189. Peter G, Pizzo P, Robichaud K, et al. Possible protective effect of circulating antibodies to the shared glycolipid of enterobacteriaciae in children with malignancy [abstract]. Pediatr Res 1979;13:466.
190. Boerbooms A, Jeurissen M, Wetstgeest A, et al. Methotrexate in refractory rheumatoid arthritis. Clin Rheumatol 1988;7:249-56.
191. Butler W, Rossen R. Effects of corticosteroids on immunity in man. J Clin Invest 1973;52:2629-40.
192. Andersen P, West S, O'Dell J, et al. Weekly pulse methotrexate in rheumatoid arthritis; clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
193. Dennin RH, Schulz E, Sack K, et al. Influence of immunosuppressive therapy with azathioprine and prednisolone on serum-immunoglobulin concentration in renal transplanted patients. Klin Wochenschr 1985;63:1110-6.
194. Gorski A, Korczak-Kowalska G, Nowaczyk M, et al. The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology 1983;6:259-66.
195. Ogilvie GK, Felsburg PJ, Harris CW. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988;18:119-27.
196. Ten Berge R, Schellekens P. A critical analysis of the use of azathioprine in clinical medicine. Neth J Med 1983;26:164-71.
197. Doria G, Agarossi G, Adorni L. Selective effects of ionizing radiation on the immunoregulatory cells. Immunol Rev 1982;65:23-54.
198. Feldman S, Gigliotti F, Bockhold C, et al. Measles and rubella antibody status in previously vaccinated children with cancer. Med Pediatr Oncol 1988;16:308-11.
199. Borella L, Webster R. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Cancer 1971;31:420-6.
200. Ridgway D, Wolff L, Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child 1991;145:887-91.
201. Rautonen J, Siimes M, Lundstrom H, et al. Vaccination of children during treatment for leukemia. Acta Paediatr 1986;75:579-85.
202. Lange B, Jakacki R, Nasab A, et al. Immunization of leukemic children with Haemophilus conjugate vaccine. Pediatr Infect Dis J 1989;8:883-4.
203. Mitus A, Holloway A, Evans AE, et al. Attenuated measles and mumps vaccine in children with acute leukemia. Am J Dis Child 1962;103:243-8.
204. Torigoe S, Hirai S, Oitani K, et al. Application of live attenuated measles and mumps vaccines in children with acute leukemia. Biken J 1981;24:147-51.
205. Dupuy JM, Kourilsky FM, Fradelizzi D, et al. Depression of immunologic reactivity of patients with acute leukemia Cancer 1971;27:323-31.
206. Bosu SK, Ciudad H, Sinks LF, et al. Antibody response to poliovirus immunization in childhood leukemia. Med Pediatr Oncol 1975; 1:217-25.
207. Arbeter AM, Granowetter L, Starr SE, et al. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 1990;85:338-44.
208. Oka T, Iseki K, Oka R, et al. Evaluation of varicella vaccine in childhood leukemia. Observation over 6 years. Biken J 1984;27:103-9.
209. Ha K, Baba K, Ikeda T, et al. Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy. Pediatrics 1980;65:346-50.
210. Entacher U, Jurgenssen O, Thun-Hohenstein L, et al. Hepatitis B vaccination and immune response in children with malignant diseases. Eur J Pediatr 1985;144:160-3.
211. Allison JE, Glezen WP, Taber LH, et al. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. J Infect Dis 1977;136 Suppl:S672-6.
212. Brown AE, Steinherz PG, Miller DR, et al. Immunization against influenza in children with cancer: results of a three-dose trial. J Infect Dis 1982;145:126.
213. Gross PA, Lee H, Wolff JA, et al. Influenza immunization in immunosuppressed children. J Pediatr 1978;92:30-5.
214. Gigliotti F, Feldman S, Shenep J, et al. Response of children with acute lymphoblastic leukemia (ALL) to H. influenzae type B (HiB) conjugate vaccine. Pediatr Res 1988;23:369A.
215. Ridgway D, Wolff LJ. Active immunization of children with leukemia and other malignancies. Leuk Lymphoma 1993;9:177-92.
216. Brunell P, Shehab Z, Geiser C, et al. Administration of live varicella vaccine to children with leukemia. Lancet 1982;ii:1069-72.
217. Gershon A, Steinberg S. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella virus. N Engl J Med 1989;320:892-7.
218. Brunell P, Taylor-Wiedeman J, Geiser C, et al. Risk of herpes zoster in children with leukemia: Varicella vaccine compared with history of chicken pox. Pediatrics 1986;77:53-6.
219. Hardy I, Gershon A, Steinberg S, et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 1991;325:1545-50.
220. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous Immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-7.
221. Yap PL. Prevention of infection in patients with B cell defects: focus on intravenous immunoglobulin. Clin Infect Dis 1993;17 Suppl 2:S372-5.
222. Lakomek M, Tillmann W, Schrewe H, et al. Specific immunoglobulin and acyclovir in the prevention and treatment of varicella zoster infections in children with neoplastic diseases. Klin Padiatr 1986;198:281-4.
223. Straus SE, Ostrove JM, Inchauspe G, et al. Varicella-Zoster virus infection. Biology, natural history, treatment, and prevention. Ann Intern Med 1988;108:221-37.
224. Bratanow NC, Ash RC, Turner PA. Successful treatment of serious cytomegalovirus (CMV) disease with 9(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir). DHPG and intravenous immunoglobulin (IVIG) in bone marrow (BMT) transplant patients [abstract 254]. Exp Hematol 1987;15:541.
225. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777-82.
226. Lehrnbecher T, Schrod L, Kraus D, et al. Interleukin-6 and soluble interleukin-6 receptor in cord blood in the diagnosis of early onset sepsis in neonates. Acta Paediatr 1995;84:806-8.
227. Lehrnbecher T, Schrod L, Rutsch P, et al. Immunologic parameters in cord blood indicating early-onset sepsis. Biol Neonate 1996;70:206-12.
228. Frieling JT, van Deuren M, Wijdenes J, et al. Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis 1995; 171:469-72.
229. Martich GD, Danner RL, Ceska M, et al. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991; 173:1021-4.
230. Ostermann H, Rothenburger M, Mesters RM, et al. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 1994;88:332-7.
231. Steinshamn S, Brekke OL, Waage A. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever. Br J Haematol 1995;89:719-24.
232. Steinmetz HT, Herbertz A, Bertram M, et al. Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis. J Infect Dis 1995;171:225-8.
233. Herrmann JL, Blanchard H, Brunengo P, et al. TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 1994;22:309-15.
234. Heney D, Lewis IJ, Evans SW, et al. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis 1992;165:886-90.
235. Bruserud O, Akselen PE, Bergheim J, et al. Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections. Br J Haematol 1995;91:394-402.
236. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
237. Rintala E, Pulkki K, Mertsola J, et al. Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995;27:39-43.
238. Schonbohn H, Schuler M, Kolbe K, et al. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann Hematol 1995;71:161-8.
239. Waage A, Remick D, Steinshamn S, et al. Interleukin 8 in serum in granulocytopenic patients with infections. Br J Haematol 1994;86: 36-40.
240. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
241. Mohammed G, Taylor C, Dickinson A, et al. Interferon responses of peripheral blood mononuclear cells from normal and leukemic children. Br J Haematol 1986;64:789-98.
242. Nash K, Mohammed G, Nandapalan N, et al. T cell function in children with acute lymphoblastic leukemia. Br J Haematol 1993;83: 419-27.
243. Johnston C, Russel A, Kovithavongs T, et al. Measures of immunologic and inflammatory responses in vitro in rheumatoid patients treated with methotrexate. J Rheumatol 1986;13:294-6.
244. Seitz M, Loetscher P, Dewald B, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995;34:602-9.
245. Engelman RM, Rousou JA, Flack III JE, et al. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 1995;60:801-4.
246. Stosic-Grujicic S, Lukic ML. Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antagonist(s). Immunology 1992; 75:293-8.
247. Super M, Thiel S, Lu J, et al. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989;2:1236-9.
248. Turner MW. Deficiency of mannan binding protein - a new complement deficiency syndrome. Clin Exp Immunol 1991;86 Suppl 1:53-6.
249. Summerfield JA, Ryder S, Sumya M, et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995;345:886-9.
250. Garred P, Madsen HO, Hofmann B, et al. Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 1995;346:941-3.
251. Ezekowitz RA, Day LE, Herman GA. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988;167:1034-46.
252. Panarelli M, Holloway CD, Mulatero P, et al. Inhibition of lysozyme synthesis by dexamethasone in human mononuclear leukocytes: an index of glucocorticoid sensitivity. J Clin Endocrinol Metab 1994;78:872-7.
253. Coates T, Wolach B, Tzeng D, et al. The mechanism of action of the anti-inflammatory agents dexamethasone and Auranofin in human polymorphonuclear leukocytes. Blood 1983;62:1070-7.
254. Chandra R. Nutrition, immunity and infection: Present knowledge and future directions. Lancet 1983;1:688-91.
255. Gallin J, Durocher J, Kaplan A. Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest 1975;55:967-74.
256. Lemercier C, Julen N, Coulpier M, et al. Differential modulation by glucocorticoids of alternative complement protein secretion in cells of the monocyte/macrophage lineage. Eur J Immunol 1992;22: 909-15.
257. Moffat GJ, Tack BF. Regulation of C4b-binding protein gene expression by the acute-phase mediators tumor necrosis factor-alpha, interleukin-6, and interleukin-1. Biochemistry 1992;31:12376-84.
258. Higuchi T, Mori H, Niikura H, et al. Hypocomplementemia and hematological abnormalities in immunoblastic lymphadenopathy and immunoblastic lymphadenopathy-like T cell lymphoma. Acta Haematol 1996;96:68-72.
259. Schofield KP, Stone PC, Stuart J. Quantitative cytochemistry of blood neutrophils in acute myeloid leukaemia. Br J Haematol 1983;54:261-8.
260. Bezwoda WR, Dajee D. Plasma lactoferrin content in neutropenic patients: effects of treatment with recombinant granulocyte-macrophage colony-stimulating factor. Mol Biother 1992;4:103-6.
261. Tramont E, Hoover D. General or nonspecific host defense mechanisms. In: Mandell G, Bennett J, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995: 30-5.
262. Van der Meer J. Defects in Host Defense Mechanisms. In: Rubin R, Young L, eds. Clinical Approach to Infection in the Compromised Host, 2nd ed. New York: Plenum Publishers, 1994:33-66.
263. Kramer BS, Pizzo PA, Robichaud KJ, et al. Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and neutropenia. Am J Med 1982;72:561-8.
264. Fainstein V, Rodriguez V, Turk M, et al. Patterns of oropharyngeal and fecal flora in patients with leukemia. J Infect Dis 1981;144:10-8.
265. Bergmann O. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukemia. Scand J Infect Dis 1991;23:355-66.
266. Richet HM, Andremont A, Tantrede C, et al. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991;13:211-5.
267. Wiley J, Smith N, Leventhal B, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis. J Clin Oncol 1990;8: 280-6.
268. Faden HS, Bybee BL, Overall JCJ, et al. Disseminated herpes virus hominis infection in a child with leukemia. J Pediatr 1977;90:951-3.
269. Dybedal I, Lamvik J. Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. Eur J Haematol 1989;42:405-6.
270. Guiot H, Peters W, van den Brock P, et al. Respiratory failure elicited by streptococcal septicemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection 1990;18:131-7.
271. Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. Infection 1990;18:138-45.
272. Walsh T, Pizzo P. Experimental gastrointestinal and disseminated candidiasis in immunocompromised animals. Eur J Epidemiol 1992;8:477-83.
273. Merz W, Karp J, Hoagland M, et al. Diagnosis and successful treatment of fusariosis in the immunocompromised host. J Infect Dis 1988;158:1046-55.
274. Hiemenz J, Skelton J, Pizzo PA. Perspective on the management of catheter-related infections in cancer patients. Pediatr Infect Dis J 1986;5:6-11.
275. Mueller BU, Skelton J, Callender DPE, et al. A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 1992;10:1943-8.
276. Raad I, Bodey G. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197-210.
277. Pizzo P, Ladisch S, Witebsky F. Alpha-hemolytic streptococci-clinical significance in cancer patients. Med Pediatr Oncol 1978;4: 367-70.
278. Lejeune M, Sariban E, Cantinieaux B, et al. Defective polymorphonuclear leukocyte functions in children receiving chemotherapy for cancer are partially restored by recombinant human granulocyte colony-stimulating factor in vitro. J Infect Dis 1996;174:800-5.
279. Roilides E, Walsh TJ, Pizzo PA, et al. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991;163:579-83.
280. Roilides E, Pizzo PA. Modulation of host defense by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992;15:508-24.
281. Wiltschke C, Krainer M, Nanut M, et al. In vivo administration of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor increases neutrophil oxidative burst activity. J Interferon Cytokine Res 1995;15:249-53.
282. Marina NM, Shema SJ, Bowman LC, et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 1994; 23: 328-34.
283. Weite K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996;87:3143-50.
284. Roilides E, Pizzo PA. Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts. In: Pizzo PA, ed. Infectious Complications in the Immunocompromised Host. Philadelphia: W.B. Saunders Company, 1993:841-64.
285. Murray H. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988; 108: 595-608.
286. Roilides E, Uhlig K, Venzon D, et al. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 4870-7.
287. Roilides E, Lyman CA, Merlins SD, et al. Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine 1996;8:42-8.
288. Neu H. The crisis in antibiotic resistance. Science 1993;257:1064-73.